Sanofi advances flu vaccine production with FDA-approved strains for 2025-26 season
Sanofi has confirmed that it is advancing its flu vaccine production for the 2025-26 flu season, aligning with the US Food and Drug Administration (FDA)-selected ... Read More
Scribe Therapeutics unveils ELXR technology breakthrough at Keystone Symposia 2025
Scribe Therapeutics has presented new data on its Epigenetic Long-Term X-Repressor (ELXR) technology at the 2025 Keystone Symposia on Precision Genome Engineering, showcasing a significant ... Read More
Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for the fourth quarter of 2024. The company’s ... Read More
Teva and Sanofi reveal promising Phase 2b data for duvakitug in ulcerative colitis and Crohn’s disease
Teva Pharmaceutical Industries Ltd. and Sanofi have unveiled encouraging new data from their Phase 2b RELIEVE UCCD trial, highlighting the potential of duvakitug, a novel ... Read More
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ: SNY). The deal grants Sanofi exclusive rights ... Read More
Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis
The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as ... Read More
Sanofi enters exclusive talks with CD&R over $17bn Opella deal
Sanofi has confirmed its exclusive negotiations with Clayton, Dubilier & Rice (CD&R) for the sale of a 50% stake in its consumer healthcare business, Opella. ... Read More
Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has announced a significant expansion of its ongoing ... Read More
EMA approves Dupixent as first biologic for COPD with elevated eosinophils
The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease ... Read More
Lupin Limited expands global specialty portfolio with strategic acquisitions
Global pharmaceutical leader Lupin Limited (Lupin) has announced the completion of a strategic acquisition through its European hub, Lupin Atlantis Holdings SA. The company has ... Read More